This Week: Our Special Report: Inside the Challenge to DEA’s Proposed Scheduling of 5 Psychedelic Tryptamines Second Psychedelics Company Enters Into Death Spiral Financing Disturbing Documentary from Down Under and more… Special Report: Inside the Challenge to DEA’s Proposed Scheduling of 5 Psychedelic Tryptamines Last week, the DEA ditched plans to place five tryptamines on Schedule I after a…

Source

Previous articleCOMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Next articleInside the Challenge to DEA’s Proposed Scheduling of 5 Psychedelic Tryptamines